119 results
8-K
EX-1.1
EYPT
EyePoint Pharmaceuticals Inc
7 Dec 23
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
6:11pm
or other legally binding standard relating to pollution or protection of human health and the environment (“Environmental Law”), except for violations
424B5
EYPT
EyePoint Pharmaceuticals Inc
7 Dec 23
Prospectus supplement for primary offering
6:11am
and progress of any partnering efforts, technological advances, the effect of the Pandemic on our business and the competitive environment for our products
424B5
EYPT
EyePoint Pharmaceuticals Inc
4 Dec 23
Prospectus supplement for primary offering
5:31pm
and the competitive environment for our products. As of the date of this prospectus supplement, we cannot specify with certainty all of the particular uses
DEFA14A
scni3xt
28 Apr 23
Additional proxy soliciting materials
4:02pm
DEFA14A
0vjorkc5v6w6a
28 Sep 22
Additional proxy soliciting materials
4:12pm
8-K
EX-1.1
nhspg5384h7l
19 Nov 21
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
4:01pm
424B5
qowfw2vmrz 7do
18 Nov 21
Prospectus supplement for primary offering
5:13pm
424B5
4i2i4xa97gqrk28x3
16 Nov 21
Prospectus supplement for primary offering
5:13pm
DEFA14A
4qee7 0fqxscezbcl
30 Apr 21
Additional proxy soliciting materials
5:26pm